Hematology Oncology of Salem
The winner of the Cambridge Who’s Who Professional of the Year in Medical Oncology and Hematology, triple board-certified physician Natasha Tiffany, MD, treats patients at Hematology Oncology of Salem, located in Oregon. Natasha Tiffany, MD, and the office’s other qualified staff members provide care for individuals with cancer and blood disorders. The practice has a focus on designing personalized treatment plans tailored to each patient’s needs.
Despite the demand for a state-of-the-art cancer treatment center in the Salem area, residents had few options before Hematology Oncology of Salem opened in 2000. The clinic now employs eight physicians, a family nurse practitioner, and two certified physician assistants. In 2002, the practice expanded to a second clinic in McMinnville, Oregon. It also has offices in Silverton and Woodburn, Oregon.
To learn more about Hematology Oncology of Salem, please visit www.hemoncofsalem.com. Among other information, the website contains video testimonials from patients who with the help of the practice have beaten cancer and blood disorders.
Natasha Tiffany, MD, has an extensive background as a board-certified hematologist and oncologist. One of the conditions that Natasha Tiffany, MD, treats is iron deficiency.
Iron does many things for the body and is used in the majority of cell functions. Therefore, iron deficiency can affect multiple systems and organs.
Iron deficiency occurs when there is not enough iron circulating in the blood. This type of deficiency is one of the most common nutritional deficiencies in the United States. There is a quick test that can be done to show if someone lacks enough iron in the blood.
Iron deficiency can delay an infant’s motor function, mental function, and processing skills. If a woman is pregnant and has iron deficiency, it places the pregnancy at high risk and increases the risk of a pre-term delivery. Fatigue is a major sign of iron deficiency, as are pale skin and shortness of breath.
Oberlin Conservatory of Music
Natasha Tiffany, MD, is a hematology and oncology specialist based in Salem, Oregon, who is currently active in the development and management of the Salem Cancer Institute. Apart from her medical training, Natasha Tiffany, MD, is also a classically trained pianist who completed the piano program at the prestigious Oberlin Conservatory of Music.
The Ohio-based Oberlin Conservatory of Music is the oldest such institution in the US, and is noted for maintaining an outstanding reputation, consistently being cited as one of the best music schools in the country. Oberlin also initiated several innovations in music education,
Oberlin College and Conservatory is credited with being the birthplace of the double degree, whereby graduates leave with another concentration besides music. The double degree has become a prime consideration for high-achieving students to consider Oberlin. The program enables students with multiple talents and interests to satisfy more than one of them at the same time.
Natasha Tiffany, MD, currently provides a range of cancer treatments to patients at Hematology Oncology of Salem in Salem, Oregon, where she has worked since 2004. We recently sat down with Dr. Tiffany to discuss her work and the types of cancer therapies she offers to patients.
Can you tell us a little bit about some of the research that you have conducted over the course of your career?
Natasha Tiffany, MD: Of course. For two years in the early 2000s, I worked with Dr. Tomasz Beer studying the effectiveness of two drugs, Zometa and Gleevec, on androgen-independent prostate cancer. With Dr. Beer, I have also published research on the effects of Docetaxel, Calcitriol, and Estramustine in androgen-independent prostate cancer. I have participated in the research of multiple myeloma, as well. My earlier research was in neurology, particularly looking at stroke and Parkinson’s disease.
You also have been involved in cancer research through other professional activities. Can you discuss some of those?
Natasha Tiffany, MD: At the Salem Cancer Institute, we are building our clinical trials program so we can offer cutting-edge treatments to patients that have not yet been FDA approved. I believe clinical research is vital to the future of cancer treatments, and it can offer important drugs that patients otherwise would not have been able to receive. We are hoping to have a clinical trial available for each of the major stages of most cancers so that we can offer these trials to those patients who are interested. I serve on the Board of Directors for Willamette Clinical Research and am a member of the Southwest Oncology Group, which designs and funds clinical trial.